These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16012793)

  • 1. DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors.
    Wente MN; Kleeff J; Büchler MW; Wanders J; Cheverton P; Langman S; Friess H
    Invest New Drugs; 2005 Aug; 23(4):339-47. PubMed ID: 16012793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.
    Soepenberg O; de Jonge MJ; Sparreboom A; de Bruin P; Eskens FA; de Heus G; Wanders J; Cheverton P; Ducharme MP; Verweij J
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):703-11. PubMed ID: 15701859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f, in tumor-bearing mice.
    Masubuchi N
    Pharmazie; 2004 May; 59(5):374-7. PubMed ID: 15212304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies.
    Braybrooke JP; Boven E; Bates NP; Ruijter R; Dobbs N; Cheverton PD; Pinedo HM; Talbot DC
    Ann Oncol; 2003 Jun; 14(6):913-21. PubMed ID: 12796030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity in several tumors.
    Shiose Y; Ochi Y; Kuga H; Yamashita F; Hashida M
    Biol Pharm Bull; 2007 Dec; 30(12):2365-70. PubMed ID: 18057727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.
    Boige V; Raymond E; Faivre S; Gatineau M; Meely K; Mekhaldi S; Pautier P; Ducreux M; Rixe O; Armand JP
    J Clin Oncol; 2000 Dec; 18(23):3986-92. PubMed ID: 11099328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
    Rowinsky EK; Johnson TR; Geyer CE; Hammond LA; Eckhardt SG; Drengler R; Smetzer L; Coyle J; Rizzo J; Schwartz G; Tolcher A; Von Hoff DD; De Jager RL
    J Clin Oncol; 2000 Sep; 18(17):3151-63. PubMed ID: 10963644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma.
    Sarapa N; Britto MR; Speed W; Jannuzzo M; Breda M; James CA; Porro M; Rocchetti M; Wanders A; Mahteme H; Nygren P
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):424-30. PubMed ID: 12904897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
    Giles FJ; Cortes JE; Thomas DA; Garcia-Manero G; Faderl S; Jeha S; De Jager RL; Kantarjian HM
    Clin Cancer Res; 2002 Jul; 8(7):2134-41. PubMed ID: 12114413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.
    Sharma S; Kemeny N; Schwartz GK; Kelsen D; O'Reilly E; Ilson D; Coyle J; De Jager RL; Ducharme MP; Kleban S; Hollywood E; Saltz LB
    Clin Cancer Res; 2001 Dec; 7(12):3963-70. PubMed ID: 11751488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks.
    Minami H; Fujii H; Igarashi T; Itoh K; Tamanoi K; Oguma T; Sasaki Y
    Clin Cancer Res; 2001 Oct; 7(10):3056-64. PubMed ID: 11595695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
    Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Topoisomerase I inhibitor (irinotecan hydrochloride)].
    Inoue S; Hassan MK; Kanetoshi A
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():456-60. PubMed ID: 15658362
    [No Abstract]   [Full Text] [Related]  

  • 14. A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.
    Garrison MA; Hammond LA; Geyer CE; Schwartz G; Tolcher AW; Smetzer L; Figueroa JA; Ducharme M; Coyle J; Takimoto CH; De Jager RL; Rowinsky EK
    Clin Cancer Res; 2003 Jul; 9(7):2527-37. PubMed ID: 12855627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog.
    Royce ME; Hoff PM; Dumas P; Lassere Y; Lee JJ; Coyle J; Ducharme MP; De Jager R; Pazdur R
    J Clin Oncol; 2001 Mar; 19(5):1493-500. PubMed ID: 11230496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation study of a method for assaying DE-310, a macromolecular carrier conjugate containing an anti-tumor camptothecin derivative, and the free drug in human plasma by HPLC and LC/MS/MS.
    Oguma T; Cicci D; Gaudette F; Gauthier-Dubois G; Guilbaud R; Atsumi R
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Apr; 818(2):249-56. PubMed ID: 15734166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951.
    Ochi Y; Shiose Y; Kuga H; Kumazawa E
    Cancer Chemother Pharmacol; 2005 Apr; 55(4):323-332. PubMed ID: 15517271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer.
    Ajani JA; Takimoto C; Becerra CR; Silva A; Baez L; Cohn A; Major P; Kamida M; Feit K; De Jager R
    Invest New Drugs; 2005 Oct; 23(5):479-84. PubMed ID: 16133799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation study of a method for assaying DE-310, a macromolecular carrier conjugate containing an anti-tumor camptothecin derivative, and the free drug in tumor tissue by high performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry.
    Oguma T; Morikawa H; Iwasaki D; Atsumi R
    Biomed Chromatogr; 2005 Jan; 19(1):19-26. PubMed ID: 15484225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma.
    Esteva FJ; Rivera E; Cristofanilli M; Valero V; Royce M; Duggal A; Colucci P; DeJager R; Hortobagyi GN
    Cancer; 2003 Sep; 98(5):900-7. PubMed ID: 12942555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.